0
Startups & Venture·October 6, 2026·1 min read

Dimensional PM on IPO Pipeline, Concentration Risks

Share

A 10% Q3 drop in deal value after a first half with 47 $10B+ deals says more about concentration than health—capital is still there, just choosier. Late-stage founders should expect higher scrutiny on post-IPO performance and be ready to defend why they won’t join the historical underperformance cohort.